1. Montanari NR, RamírezR, AggarwalA, Van BuurenN, Doukas M, MoonC, TurnerS, Diehl L, LiL, Debes JD, Feierbach B, Boonstra A. Multi-parametric analysis of human livers reveals intrahepatic inflammation variation across chronic hepatitis B infection phase. J Hep. 2022. Available online.
  2. Weber J, Gehring A, Mendez P, Richter K, Ertl H, Donaldson E, Mishra P, Maini M, Boonstra A, Lauer G, de Creus A, Whitaker K, Ferrando-Martinez S, Miller V. Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection. J Hep. 2022. Available online.
  3. Sonneveld MJ, Chiu S-M, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T,Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen C-H, Maasoumy B. HBsAg loss after nucleo(s)tide analogue withdrawal: relationship with HBV genotype and viral antigen levels. J Hep. 2022. Available online.
  4. Montanari NR, RamirezR, van BuurenN, van den BoschTPP, DoukasM, Debes JD,Feierbach B,Boonstra A. Transcriptomic analysis of livers of inactive carriers of hepatitis B virus with distinct expression of hepatitis B surface antigen. J Inf Dis. 2022. 225 (6): 1081-1090.
  5. Sonneveld MJ, Park JY, A. Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T,Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner zu Siederdissen C, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B. for the CREATE study group. Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels – A multicenter study (CREATE). Clin Gastro Hepatol. 2022. 20(4): e784-e793.
  6. Montanari NR; Boonstra A, Anugwom C, Debes JD. The role of cytokines in the different stages of hepatocellular carcinoma. 2021. Cancers. 2021 Sep 29;13(19):4876.
  7. Sari G, Zhu J, Ambardekar C, YinX, Boonstra A, FengZ, Vanwolleghem T. The viral ORF3 protein is required for hepatitis E virus apical release and efficient growth in polarized hepatocytes and humanized mice. J Virol. 2021. 95(23): e0058521.
  8. Sari G, Mulders CE, Zhu J, van Oord GW, Feng Z, Kreeft-Voermans JJC, Boonstra A, Vanwolleghem T. Treatment induced clearance of HEV by IFN-lambda in liver humanized mice. Liver Intern. 2021. 41(12):2866-2873.
  9. Mattos AZ, Debes JD, Boonstra A, VogelA, Mattos AA. Immune aspects in hepatocellular carcinoma – from immune markers for early detection to immunotherapy. World J Gastrointestinal Oncology. 2021. 13(9): 1132-1143.
  10. Beudeker BJB, Janssen HLA, Boonstra A. Letter to the Editor:  Entecavir treatment restores the anti-hepatitis B virus immune response? 2021. Hepatology. Accepted
  11. Beudeker BJB, Voermans JJC, Geurtsvankessel CH, de Knegt RJ, KuhlemannT, Boonstra A, van der Eijk AAPrevalence of hepatitis delta virus among chronic hepatitis B carriers in a large tertiary center in the Netherlands. 2021 J Clin Virol. Accepted
  12. MattosAZ, Debes JD Andre Boonstra A, Yang JD, Balderramo DC, Sartori GDP, Mattos AA. Current impact of viral hepatitis on liver cancer development – the challenge remains. 2021. World J Gastroenterol. Accepted.
  13. Debes JD, Romagnoli P, Prieto J, Arrese M, Mattos AZ, Boonstra A. On behalf of the ESCALON Consortium. Serum biomarkers for the prediction of hepatocellular carcinoma. Cancers. Apr 2;13(7):1681.
  14. Sari G, van Oord GW, van de Garde MBD, Voermans JJC, Boonstra A, Vanwolleghem T. Sexual dimorphism in hepatocyte xenograft models. Cell Transplantation. 2021. 30:9636897211006132.
  15. Kuscuoglu D, Kathrin Wenzel, Lisa Bewersdorf, Annika Gross, Gökce Kobazi Ensari, Kanishka Hittatiya, Nicole Golob-Schwarzl, Rudolf Leube, Christian Preisinger, Jacob George, Mayada Metwally, Mohammed Eslam, Pietro Lampertico, Salvatore Petta, Alessandra Mangia, Thomas Berg, Andre Boonstra, Willem P Brouwer, Maria Lorena Abate, Alessandro Loglio, Angela Sutton, Pierre Nahon, Benedikt Schäfer, Heinz Zoller, Elmar Aigner, Christian Trautwein, Johannes Haybaeck, Pavel Strnad.Dual proteotoxic stress promotes the development of liver injury via autophagy overload and activation of p62-Nrf2. J Pathology. 2021. 254: 80-91
  16. Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol. 2021. 362: 104283.
  17. Brunetto MR, Carey I, Maasoumy B, Marcos-Fosch C, Boonstra A, Caviglia GP, Loglio A, Cavallone D, Scholtes C, Ricco G, Smedile A, Riveiro Barciela M, van Bömmel F, van der Eijk A, Zoulim F, Berg T, Cornberg M, Lampertico P, Agarwal K, Buti M. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. Alim Pharm Ther. 2021. 53(6): 733-744
  18. Sonneveld MJ, Park JY, A. Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T,Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner zu Siederdissen C, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B. for the CREATE study group. Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels – A multicenter study (CREATE). Clin Gastro Hepatol. 2020. Accepted.
  19. Brakenhoff SM, de Man RA, Erler NS, Boonstra A, van CampenhoutMJH, de KnegtRJ, van BömmelF, van der EijkAA, BergT, HansenBE, JanssenHLA, Sonneveld MJ. HBV RNA decline without concomitant HBsAg decrease is associated with a low probability of sustained response and HBsAg loss. Alim Pharm Ther. 2021. 53(2):314-320.
  20. Montanari NR, Conceição-Neto N, Van Den WyngaertI, Van Oord GW, GroothuisminkZMA, Van TilburgS, de Man RA, AerssensJ, Boonstra A. Differential gene expression in peripheral blood between low viremic inactive carrier and NUC-treated HBV patients irrespective of circulating HBsAg levels. J Inf Dis. 2020. Available online.
  21. Beudeker BJ, Groothuismink, ZMA, De Man RA, Witjes C, van der Eijk A, Boonstra A, Sonneveld MJ.  Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV associated early stage hepatocellular carcinoma: Results from a Dutch long-term follow-up study. J Vir Hep. 2020. Accepted.
  22. Beudeker BJ, Groothuismink ZM, de Man RA, Janssen H, van der Eijk AA, Boonstra A, Sonneveld MJ. Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B. Antivir Ther. 2020. Accepted
  23. Debes JD, Groothuismink ZMA, de Man RA, Boonstra A. Association between a progesterone receptor mutation and hepatitis E sero-positivity in liver transplant recipients. J Med Virol. 2020. Accepted.
  24. Shen S, Wong GL-H, Kuang Z, van Campenhout MJH, Fan R, Wong VW-S, Yip TC-F  Chi H, Liang X, Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J,  Sun J, Chan HL-Y. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir‐treated patients with chronic hepatitis B. J Med Virol. 2020. Accepted.
  25. Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology. 2020. Accepted.
  26. Hakim MS. Jariah ROA, Spaan M, Boonstra A. Interleukin 15 upregulates the expression of PD-1 and TIM-3 on CD4+ and CD8+ T cells. Amer J Clin Exp Immunol. 2020. Accepted. 
  27. Boeijen LL, Spaan M, Boonstra A. The effect of nucleo(s)tide analogs on host immune cells: the baseline for future immune therapy for HBV? Antiviral Therapy. 2020. Accepted
  28. Debes JD, van Oord GW, Boonstra A. Validation of whole blood rapid diagnosis test for hepatitis B. Annals of Global Health. 2020. Accepted
  29. Van CampenhoutMJH, van BömmelF, Pfefferkorn M, FischerJ, DeichselD, Boonstra A, van VuurenAJ, BergT, Hansen BE, Janssen HLA.. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg positive chronic hepatitis B. J Vir Hep. 2020. Accepted
  30. Vanwolleghem T, Groothuismink ZMA, Kreefft K, Hung M, Novikov N, Boonstra A. Potent Hepatitis B core-specific memory B cell responses associate with clinical parameters in chronic HBV patients. J Hepatol. 2020. Accepted.
  31. Debes JD, Boonstra A, de Knegt RJ. NAFLD-related HCC and the four horsemen of the Apocalypse. Hepatology. 2020. 71(3):  774-776.
  32. Hoogeveen RC, Boonstra A. Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic hepatitis B virus infection. Frontiers in Immunol. 2020. 11; 401.
  33. Sari G, Meester EJ, van der Zee LC, Wouters K, van Lennep JR, Peppelenbosch M, Boonstra A, Van der Heiden K, Mulder MMT,Vanwolleghem T. A mouse model of humanized liver shows a human-like lipid profile, but does not form atherosclerotic plaque after western type diet. Biochem Biophys Res Commun. 2020. 524(2):510-515.
  34. Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bömmel F, Janssen HLA. HBV-RNA in serum as early predictor for response to PEGylated interferon alfa treatment in HBeAg negative chronic hepatitis B. Clin Infec Dis. 2019. Accepted.
  35. Sari G, van de Garde MDB, van Schoonhoven A, Voermans JC, van der Eijk AA, de Man RA, BoonstraA, Vanwolleghem T, Pas SD. HEV shows more genomic alterations in vitro than in vivo. Pathogens. 2019. 8(4):255.
  36. Shen S,  Lai-Hung Wong G, Kuang Z, van Campenhout MJH, Fan R, Wai-Sun Wong V,  Yip TC, Chi H,  Liang X,  Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J,  Sun J, Lik-Yuen Chan H. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated chronic hepatitis B patients. J Med Virol. 2020. Accepted.
  37. Debes JD, GroothuisminkZMA, DoukasM, de ManRA, Boonstra A. Acute genotype 3 cholestatic hepatitis E in an immune-competent host with intrahepatic-only replication. Clinical and Molecular Hepatology. 2019.
  38. Debes JD, Carrera E, Mattos AZ, Prieto JE, Boonstra A. Hepatocellular carcinoma, a unique tumor with a lack of biomarkers. Ann Hepatol. 2019. 18(6):786-787.
  39. LeathersJ, PisanoMB, ReV, van OordG, SultanA, Boonstra A, Debes JD. Evaluation of rapid diagnostic tests for assessment of hepatitis B in resource limited settings. Ann Global Health. 2019. 11(4):314-315.
  40. Debes JD, Boonstra A, Balderramo D, Mattos AZ, Arrese M. Hepatobiliary cancers in South America, where disparity strikes. Lancet Gastro Hepatol. 2019. 4(8): 581.
  41. Das T, Bergen IM, Koudstaal T, van Hulst JAC, van Loo G, Boonstra A, Vanwolleghem T, Leung PSC, Reis e Sousa C, Hendriks RW, Kool M. T cell and B cell homeostasis is controlled by A20/Tnfaip3 levels in DNGR1+ DCs inducing autoimmune liver pathology. J Autoimmun. 2019. 102: 167-178.
  42. Revill PA, Block J, Chisari F, Dandri M, Gehring, A, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang J, Lim SG, Lu F, Penicaud C, Tavis J, Thimme R, Members of the ICE-HBV Working Groups, ICE-HBV Stakeholders Group Chairs, ICE-HBV Senior Advisors, and Zoulim F. The International Coalition to Eliminate Hepatitis B (ICE-HBV) – A Global Scientific Strategy towards Cure of Chronic Hepatitis B Virus Infection. Lancet Gastro Hepatol. 2019. 4(7): 545-558.
  43. Soares E, Groothuismink ZMA, Boonstra A, Bolges O. Glucan particles are a powerful adjuvant for the HBsAg, favoring antiviral immunity. Mol Pharmaceutics. 2019. 16(5): 1971-1981.
  44. Van Halewijn GJ, Geurtsvankessel CH, Klaasse J, van Oord GW, de Knegt RJ, van Campenhout MJ, Boonstra A, van der Eijk AA. Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. J Clin Virol. 2019. 114: 1-5.
  45. Sonneveld MJ, van Oord GW, van Campenhout MJ, de Man RA, Janssen HLA, de Knegt RJ, Boonstra A, van der Eijk AA. Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Vir Hep. 2019. 26(7): 828-834.
  46. Brouwer WP, ChanHLY, Lampertico P, HouJ, Tangkijvanich P, W Reesink HW, Zhang W, MangiaA, Tanwandee T, MontaltoG, SimonK, OrmeciN, ChenL, TabakF, GunsarF, FlisiakR, FerenciP, AkdoganM, Akyuz F, Hirankarn N, JansenL, WongV, Liang X, Shalom ChenS, GroothuisminkZMA, JaroszewiczJ, OzarasR, KozbialK, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, SunJ, Hansen BE, Boonstra A, JanssenHLA. For the GIANT-B Global Consortium. Genome wide association study identifies variants associated with early and sustained response to interferon in chronic hepatitis B patients: the GIANT-B study. Clin Inf Dis. 2019. Available online.
  47. LeathersJ, Pisano MB, ReV, van OordG, SultanA, BoonstraA, Debes JD. Validation of a point-of-care rapid diagnostic test for hepatitis C for use in resource-limited settings. International Health. 2019. 11(4): 314-315.
  48. BoeijenLL, van Oord GW, HouJ, van der Heide-MulderM, GaggarA, LiL, FletcherSP, de KnegtRJ, Boonstra A. Gene expression profiling of human tissue resident immune cells: comparing blood and liver. J Leukoc Biol. 2019. 105(3): 603-608.
  49. HoogeveenRC, Robidoux MP, Schwarz T, Cheney JA, Kvistad D, Aneja J, Chung RT, Boonstra A, KimAY, Timm J, Lewis-Ximenez LL, Tonnerre P, and Lauer GM. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut. 2019. 68(5):893-904.
  50. Shah SM, Baniya JB, Gupta B, Shrestha A, Rodin H, Boonstra A, Debes JD. Association between liver fibrosis and Hepatitis E seroprevalence among HIV-positive individuals in Nepal. Eur J Gastroenterol Hepatol. 2019. 31(4): 503-505.
  51. Van Campenhout MJH, Rijckhorst V, Brouwer WP, Ferenci P, Tabak F, Akdogan M, Pinarbasi B, Simon K, Raptopoulou-Gigi, van Oord G, de Knegt RJ, Boonstra A, Janssen HLA, Hansen BE. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J Vir Hep. 2019. Available online.
  52. Boeijen LL, Hou J, de GroenRA, VerbonA, Boonstra A. Persistent replication of HIV, HCV and HBV results in distinct gene expression profiles by human NK cells. J Virol 2019. Accepted.
  53. El Sharkawy R, Thabet K, Lampertico P, PettaS, MangiaA, BergT, MetwallyM, BoonstraA, Brouwer WP, Lorena AbateM, D’AmbrosioR, DouglasMW, KhanA, FischerJ, LiddleC, GeorgeJ, Eslam M. STAT4 variants increase liver fibrosis risk in chronic hepatitis B through impaired STAT4-dependent NK cell IFN-γ production. Alim Pharm Ther. 2018. 48(5):564-573.
  54. Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Hosseini Razavi A, Sharifian A. Characterization of the “a” determinant region of the hepatitis B virus genome in Iranian patients at different clinical phases of chronic infection. Gastroenterol Hepatol Bed Bench. 2018. 11(2):131-137.
  55. Peltenburg NC, Schoeman JC, Hou J, Mora F, Harms AC, Lowe SH, Bierau J, Bakker JA, Verbon A, Hankemeier T, Boonstra A. Persistent metabolic changes in HIV infected patients during the first year of combination antiretroviral therapy. Scientific Reports. 2018 Nov 16;8(1):16947.
  56. Buschow SI, P Biesta, NS Erler, ZMA Groothuismink, T Vanwolleghem, I Najera, M Ait-Goughoulte, A Boonstra, AM Woltman. TLR7 polymorphism, HBV infection and sex affect plasmacytoid DC phenotypic maturation by TLR7 (but not TLR9) ligands. Antivir Res. 2018 Sep;157:27-37.
  57. Debes JD, Pas SD, Groothuismink ZMA, van der Ende ME, de Man RA, Boonstra A. A mutation in the progesterone predisposes to HEV infection in HIV-positive patients. Liver Int. 2018. 38(5):792-796.
  58. Van Campenhout MJH, van Bommel F, Grossmann M, Fischer J, Deichsel D, Boonstra A, van Vuuren A, Berg T, Hansen BE, Janssen HLA. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology. 2018 Sep;68(3):839-847.
  59. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze zur Wiesch J, von Felden J, de KnegtRJ, Boonstra A. Serum immune signatures associated with HCC development in DAA-treated HCV patients. Gastroenterology. 2018. Feb; 154(3):515-517.
  60. Beudeker BJ, van Oord GW, Arends JA, Schulze zur Wiesch, van der Heide M, de Knegt RJ, Verbon A, Boonstra A, Claassen MAA. MAIT cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with mild versus advanced fibrosis. Liver Int. 2018. Mar;38(3):458-468.
  61. Boeijen LL, Montanari NR, de Groen RA, van Oord GW, van der Heide M, de Knegt RJ, Boonstra A. Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy. J Inf Dis. 2017. 216(8):969-976
  62. Shrestha A, Adhikari A, Bhattarai M, Rauniyar R, Debes JD, Boonstra A, Lama TK, Al Mahtab M, Butt A, Fazle Akbar SM, Aryal N, Karn S, Das Manandhar K, Gupta BP. Prevalence and risk of hepatitis E virus infection in the HIV population of Nepal. Virology J. 2017. Nov 21;14(1):228.
  63. Van de Garde M, Pas SD, van Oord GW, Gama L, Choi Y, de Man RA, Boonstra A, Vanwolleghem T. Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Scientific Reports. 2017. 7(1):8267.
  64. Hou J, Brouwer WP, Kreefft K, Janssen HLA, French PJ, Vanwolleghem T, Boonstra.A.Unique liver transcriptomics profiles in chronic hepatitis B: intrinsic intrahepatic functional clusters discriminate distinct clinical phases. PlosOne. 2017. 12(6):e0179920.
  65. Van den Dries L, Claassen MAA, Groothuismink ZMA,van Gorp E, Boonstra A. Immune activation in prolonged cART-suppressed HIV patients is comparable to that of healthy controls. Virology. 2017. 509:133-139.
  66. Boeijen LL, Hoogeveen RC, Boonstra A, Lauer GM. Hepatitis B virus infection and the immune response: the big questions. Best Pract Res Clin Gastroenterol. 2017. 31(3):265-272.
  67. De Groen RA, Groothuismink ZMA, van Oord GW, Kootstra NA, Janssen HLA, Prins M, Schinkel J, Boonstra A. NK cells in self-limited HCV infection exhibit a more extensively differentiated CD57+/KIR+ and NKG2A, but not memory-like, repertoire. J Vir Hep. 2017. 24: 917-926.
  68. Brouwer WP, van der Meer AJ, Boonstra A, Plompen EPC, Pas SD, de Knegt RJ, de Man RA, ten Kate FJW, Janssen HLA, Hansen BE. The PAGE-B score accurately predicts clinical outcome and outperforms other biomarkers over 15 years of follow-up in a diverse cohort of chronic hepatitis B patients. J Vir Hep. 2017. 24: 1023-1031.
  69. Hullegie SJ, Arends JEA, Groothuismink ZMA, Pas SD, Rijnders BJA, Boonstra A, Claassen MAA. Decreased pro-inflammatory immune responses during recurrent acute HCV re-infections in HIV co-infected patients. J Gen Virol 2017. 98(6): 1294-1298.
  70. Vanwolleghem T, Boonstra A. Focus on the liver: host–virus interactions in HBV. J Hepatol. 2017. 66(5): 884-885.
  71. Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Sharifian A. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. J Vir Hep. 2017. 24(9): 776-788.
  72. De Groen RA, Hou J, van Oord GW, Groothuismink ZMA, van der Heide M, de Knegt RJ, Boonstra A. NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection. Antivir Res. 2017. 140:18-24.
  73. Thabet  K, ChanHL, Petta S, Mangia A, BergT, BoonstraA, Brouwer WP, AbateML,  WongV, WhiteR,  FischerJ, Liddle C, GeorgeJ, Eslam M. The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology. 2017. 65(6): 1840-1850.
  74. Debes JD, de Knegt RJ, Boonstra A. The path to cancer, and back: Immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals. Transplantation. 2017. 101(5):910-915.
  75. Debes JD, Janssen HLA, Boonstra A. Hepatitis C treatment and liver cancer recurrence: cause for concern? Lancet Gastroenterology and Hepatology. 2017. 2(2): 78-80.
  76. Van de Garde MDB, Movita D, van der Heide M, Herschke F, de Jonghe S, Gama L, Boonstra A, Vanwolleghem T. Liver monocytes and Kupffer cells remain transcriptionally distinct during chronic viral infection. PlosOne. 2016. 11(11):e0166094.
  77. Debes JD, Bohjanen PR, Boonstra A. Mechanisms of accelerated liver fibrosis progression during HIV infection. J Clin Transl Hepatol. 2016. 4(4): 328-335.
  78. Verstrepen BE, Nieuwenhuis IG, Mooij, Verschoor EJ, Fagrouch ZC, Kondova I, Boonstra A, Koopman G. Role for microbial translocation in soluble CD14 up-regulation in HIV, but not in HCV, infected chimpanzees. J Gen Virol. 2016. 97(10): 2599-2607.
  79. Spaan M, Hullegie SJ, Beudeker BJB, Kreefft K, van Oord GW, Groothuismink ZMA, van Tilborg M, Rijnders B, de Knegt RJ, Claassen MAA, Boonstra A. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/ HIV co-infection and do not recover during therapy. PlosOne. 2016.11(7): e0159243.
  80. Schoeman JC, HouJ, HarmsAC, Vreeken RJ, Berger R, Hankemeier T, Boonstra A. Integrating metabolomics and transcriptomics to characterise the natural progression of chronic hepatitis B. Genome Medicine. 2016. 8(1): 64.
  81. Tjwa ETTL, Zoutendijk R, van Oord GW, Boeijen LL, Reijnders JGP, van Campenhout MJH, de Knegt RJ, Janssen HLA, Woltman AM, Boonstra A. Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). Antivir Res. 2016. 132: 396-404.
  82. Van Campenhout MJH, Brouwer WP, van Oord GW, Xie Q, ZhangQ, Zhang N, Guo S, Tabak F, Streinu-Cercel A, Wang J.-Y, Pas SD, Sonneveld MJ, de Knegt RJ, Boonstra A, Hansen BE, Janssen HLA. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infection. 2016. 22(6): 571.e5-9.
  83. Van de Garde MDB, Pas SD, van der Net G, Osterhaus ADME, Haagmans BL, Boonstra A, Vanwolleghem T. Hepatitis E virus genotype three infection of human liver chimeric mice as a model for chronic HEV infection.J Virol. 2016. 90: 4394-4401.
  84. Verstrepen B, Nieuwenhuis I, Mooij P, Bogers W, Boonstra A, Koopman G. Spontaneous and NCR mediated cytotoxicity are effector functions of distinct NK subsets in HCV infected chimpanzees. Clin Exp Immunol. 2016. 185: 42-49.
  85. Schoufour JD, Echteld MA, Boonstra A, Groothuismink ZMA, Evenhuis HM. Biochemical measures and frailty in people with intellectual disabilities. Age and Aging. 2016 Jan;45(1):142-148.
  86. Spaan M, van Oord G, Kreefft K, Hou J, Hansen BE, Janssen HLA, de Knegt RJ, Boonstra A. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Inf Dis. 2016. 213(2): 216-23.
  87. Vanhommerig JW, Lambers FA, Schinkel J, Geskus RB, Arends JE, van de Laar TJ, Lauw FN, Brinkman K, Gras L, Rijnders BJ, van der Meer JT, Prins M; MOSAIC (MSM Observational Study of Acute Infection With Hepatitis C) Study Group, van der Meer JT, Molenkamp R, Mutschelknauss M, Nobel HE, Reesink HW, Schinkel J, van der Valk M, van den Berk GE, Brinkman K, Kwa D, van der Meche N, Toonen A, Vos D, van Broekhuizen M, Lauw FN, Mulder JW, Arends JE, van Kessel A, de Kroon I, Boonstra A, van der Ende ME, Hullegie S, Rijnders BJ, van de Laar TJ, Gras L, Smit C, Lambers FA, Prins M, Vanhommerig JW, van der Veldt W. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. Open Forum Infect Dis. 2015 Aug 6;2(3):ofv115.
  88. Maan R, van der Meer AJ, Brouwer WP, Plompen EPC, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZMA, Hansen BE, Veldt BJ, Janssen HLA, Boonstra A, de Knegt RJ. ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection. PLoS ONE. 2015. 10(10): e0139317.
  89. Spaan M, van Oord GW, Janssen HLA, de Knegt RJ, Boonstra A. Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during triple therapy. Antivir Res. 2015. 123:86-92.
  90. Debes JD, Bohjanen PR, Boonstra A. Liver fibrosis in HIV and HCV co-infection: independent mechanisms versus collective efforts. Int J Virol AIDS. 2015. 2: 008.
  91. de Groen RA, Groothuismink ZMA, Liu BS, Boonstra A. IFN-λ is able to augment TLR-mediated activation and subsequent function of primary human B cells. J Leukoc Biol. 2015. 98: 623-630.
  92. Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus ADME, Pas SD, Janssen HLA, Boonstra A. Re-evaluation of HBV clinical phases by system biology identifies unappreciated roles for the innate immune response and B cells. Hepatology. 2015. 62(1): 87-100.
  93. Spaan M, Claassen MA, Hou J, Janssen HLA, de Knegt RJ, Boonstra A. The intrahepatic T-cell compartment does not normalize years after therapy-induced hepatitis C virus eradication. J Inf Dis. 2015. 212(3): 386-390.
  94. Movita D, van de Garde M, Biesta P, Kreefft K, Haagmans B, Zuniga E, Herschke F, De Jonghe S, Janssen HLA, Boonstra A, Vanwolleghem T. Inflammatory monocytes are the central instigators of early virus-induced liver inflammation. J Virol. 2015. 89(9): 4809-4817.
  95. Verstrepen BE, Boonstra A, Koopman G. Immune mechanisms of vaccine induced protection against chronic HCV infection in chimpanzees. World J Hepatol. 2015. 7(1): 53-69.
  96. Hou J, Boonstra A. Modulation of Toll-like receptor 9 expression by monocytes of viral hepatitis patients. Antivir Ther. 2015. 20(6): 667-668.
  97. De Graav GN, Dieterich M, Hesselink DA, Boer K, Clahsen-van Groningen MC, Kraaijeveld R, Litjens NHR, Bouamar R, Vanderlocht J, Tilanus M, Houba I, Boonstra A, Roelen DL, Claas FHJ, Betjes MGH, Weimar W, Baan CC. Follicular T-helper cells and humoral reactivity in kidney-transplant patients. Clin Exp Immunol.201. 180(2): 329-340.
  98. De Groen RA, Boltjes A, Hou J, Liu B-S, Mcphee F, Friborg J, Janssen HLA, Boonstra A. IFNλ-mediated IL-12 production in macrophages induces IFNγ production in human NK cells. Eur J Immunol. 2015. 45(1): 250-259.
  99. Boltjes A, van Montfoort N, Biesta PJ, Op den Brouw ML, Kwekkeboom J, van der Laan LJW, Janssen HLA, Boonstra A, Woltman AM. Kupffer cells interact with HBsAg in vivo and in vitro leading to pro-inflammatory cytokine production and NK cell function. J Inf Dis. 2015. 211(8):1268-1278.
  100. Spaan M, Kreefft K, Brouwer WP, de Knegt RJ, Ten Kate FJW, Vanwolleghem T, Janssen HLA, Boonstra A. CD4+CXCR5+ T cells in HCV infection are less capable of producing IL-21 but have a good ability to perform B cell help. J Hepatol. 2015. 62(2): 303-310.
  101. Brouwer WP, van der Meer AJ, Boonstra A, Pas S, de Knegt RJ, Hansen BE, ten Kate FJW, Janssen HLA. The impact of PNPLA3 (rs738409c>g) on liver histologic changes is modified by gender and overweight in chronic hepatitis B patients. Liver Int. 2015. 35(2): 438-447.
  102. Hou J, van Oord G, Groothuismink ZMA, Claassen MAA, Kreefft K, Zaaraoui-Boutahar F, van IJcken WFJ, Osterhaus ADME, Janssen HLA, Andeweg AC, de Knegt RJ, Boonstra A. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic HCV.J Virol. 2014. 88(21): 12254-12264.
  103. Hou J, Groothuismink ZMA, Koning L, Roomer R, van IJcken WFJ, Kreefft K, Liu BS, Jansen HLA, de Knegt RJ, Boonstra A. Analysis of the transcriptome and immune function of monocytes during IFNα-based therapy in chronic HCV revealed induction of TLR7 responsiveness. Antivir Res. 2014. 109: 116-124.
  104. Brouwer WP, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HLA. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Alim Pharm Ther. 2014. 40: 811-818.
  105. Boltjes A, Movita D, Woltman AM, Boonstra A. The role of Kupffer cells in viral hepatitis. J Hepatol. 2014. 61: 660-671.
  106. Boltjes A, Groothuismink ZMA, Janssen HLA, Woltman AM, Boonstra A. Monocytes from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease. PLoS ONE. 2014 May 13;9(5):e97006.
  107. Hakim MS, Spaan M, Janssen HLA, Boonstra A. Inhibitory receptor molecules in chronic hepatitis B and C Infections:  novel targets for immunotherapy? Med Rev Virol. 2014 24(2): 125-138.
  108. De Groen RA, Liu BS, Boonstra A. Understanding IFN-lambda in rheumatoid arthritis. Arthritis Res Ther. 2014. 16(1): 102.
  109. De GroenRA, McpheeF, FriborgJ, Janssen HLA, Boonstra A.Endogenous IFNλ in viral hepatitis patients. J Interferon & Cytokine Res. 2014. 34: 552-556.
  110. Claassen MAA, Janssen HLA, de Knegt RJ, Boonstra A. Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. J Hepatol. 2014. 60: 231-232.
  111. Nikolic T, Movita D, Lambers M, Ribeiro de Almeida C, Biesta P, Kreefft K, de Bruijn JW, Bergen I, Galjart N, Hendriks R, Boonstra A. The DNA-binding factor CTCF critically controls gene expression in macrophages. Cell Mol Immunol. 2014. 11: 58-70.
  112. Claassen MAA, Janssen HLA, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol. 2013. 3: 461-467.
  113. Tjwa ETTL, Zoutendijk R, van OordGW, Verhey J, Janssen HLA, Woltman AM, Boonstra A. Intrahepatic NK cell activation, but not function, is associated with HBV-DNA and HBsAg in patients with chronic hepatitis B. Liver Int. 2014. 34(3): 396-404.
  114. Spaan M, Groothuismink ZMA, Koning L, Robert R, Janssen HLA, de Knegt RJ, Boonstra A. Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients. Antiviral Res. 2013. 98: 469-475.
  115. Hotho DM, de Bruijne J, Spaan M, Treitel MA, Boonstra A, de Knegt RJ, Janssen HLA, Reesink HW. Sustained virologic response after therapy with the protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable during long-term follow-up. J Vir Hep. 2013. 20 (4): e78-81.
  116. Hotho DM, Kreefft K, Groothuismink ZMA, Janssen HLA, de Knegt RJ, Boonstra A. Natural killer cell activity and function in chronic HCV-infected patients during peginterferon and ribavirin: early effects of active substance use. Antiviral Res. 2013. 97 (3): 347-355.
  117. Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL. Serum levels of interferon gamma-inducible protein-10 and response to peginterferon therapy in HBeAg-positive Chronic Hepatitis B. J Hepatol. 2013. 58 (5): 898-903.
  118. van der MeerAJP, FaridWRR, Sonneveld MJ, de Ruiter PE, Boonstra A, van VuurenAJ, VerheijJ, HansenBE, de KnegtRJ, van der LaanLJ, Janssen HLA. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Vir Hep. 2013. 20 (3): 158-166.
  119. Boltjes A, Op den Brouw ML, Biesta PJ, BindaRS, van der MolenRG, Boonstra A, JanssenHLA, Woltman AM. Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic HBV patients. Mol Immunol. 2013. 53 (1-2): 72-78.
  120. Zoutendijk R, Sonneveld MJ, Reijnders J, van Vuuren AJ, Biesta P, Hansen BE, Boonstra A, JanssenHLA. Precore and core promoter mutants are associated with higher HBeAg seroconversion but lower disease remission rates in HBV patients treated with nucleos(t)ide analogues. J Vir Hep. 2013. 20 (5): 322-327.
  121. Claassen MAA, de Knegt RJ, Turgut D, Groothuismink ZMA, Janssen HLA, Boonstra A. Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. PLoS ONE. 2012. 7(11): e49389.
  122. Van de Laar LA, van den Bosch A, Boonstra A, Binda RS, Buitenhuis M, Janssen HLA, Coffer PJ, Woltman AM. PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function. Blood. 2012. 120 (25): 4982-4891.
  123. Spaan M, Janssen HLA, Boonstra A. Immunology of hepatitis C infections. Review. Best Pract Res Clin Gastroenterol. 2012. 26(4): 391-400.
  124. Verstrepen B, de Groot N, Groothuismink ZMA, Verschoor E, Bogers W, Janssen HLA, Mooij P, Bontrop R, Koopman G, Boonstra A. Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees. PLoS ONE. 2012.  7(10): e46645.
  125. Movita D, Kreefft K, van Oudenaren A, Leenen PJ, Janssen HLA, Boonstra A. Distinct phenotype and functions of Kupffer cells in comparison to splenic and peritoneal macrophages. J Leukocyte Biol. 2012. 92 (4): 723-733.
  126. Liu BS, Janssen HLA, Boonstra A. Type I and III interferon enhance IL-10-induced STAT3 phosphorylation in human monocytes and macrophages, at least partly via augmented IL-10 receptor expression. Eur J Immunol. 2012. 42 (9): 2431-2440.
  127. Tjwa ETTL, van Oord GW, Biesta P, Boonstra A, Janssen HLA, Woltman AM. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B. J Virology. 2012. 86(8): 4102-4109.
  128. Roomer R, Bergmann JF, Boonstra A, Hansen BE, Haagmans B, Kwadijk-de Gijsel S, van Vuuren AJ, de Knegt RJ, Janssen HLA.  Continuous interferon alfa-2b infusion in combination with ribavirin for chronic hepatitis C in treatment experienced patients. Antiviral Therapy. 2012. 17: 509-517.
  129. Boonstra A, B-S. Liu, Z.M.A. Groothuismink, J.F. Bergmann, J. de Bruijne, DM Hotho, B. Hansen, AA van Vliet, J. van de Wetering, S.P. Fletcher, L.A. Bauman, M. Rahimy, J.R. Appleman, JL Freddo, HW Reesink, RJ de Knegt, HLA. Janssen. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via TLR7. Antiviral Therapy. 2012. 17(4): 657-667.
  130. Shi CC, Tjwa ETTL, Biesta PJ, Boonstra A, Xie Q, Janssen HLA, Woltman AM.Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells. J Vir Hep. 2012. 19:e26-33.
  131. Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A, Weegink CJ, van Vliet AA, van de Wetering J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Janssen HL, Reesink HW. Randomized clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Alim Pharm Ther. 2011. 34(4): 443-453.
  132. Peng C, Liu B-S, de Knegt RJ, Janssen HLA, Boonstra A. The response to TLR ligation of human CD16+CD14 monocytes is weakly modulated as a consequence of persistent infection with the hepatitis C virus. Mol Immunol. 2011. 48: 1505-1511.
  133. Claassen MAA, de Knegt, RJ, Janssen HLA, Boonstra A. Retention of CD4+CD25+FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. J Virology. 2011. 85(11): 5323-5330.
  134. Liu B-S, Groothuismink ZMA, Janssen HLA, Boonstra A. Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections. J Leukocyte Biol. 2011. 89(6): 981-988.
  135. Liu B-S, Janssen HLA, Boonstra A. IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages, and exhibit differential regulation of the IFNg receptor expression. Blood. 2011. 117(8): 2385-2395.
  136. Redford PS, Boonstra A, Read S, Pitt, J, Graham C, Stavropoulos E, BancroftGJ, O’Garra A. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol. 2010. 40: 2200-2210.
  137. Grotenhuis BA, Franken PF, Swinkels WJC, Boonstra A, van der Valk MA, van Lanschot JJB, Fodde R. Early morbidity encountered in the dietary-related mouse model of Barrett’s esophagus: a question of zinc? Dis Esophagus. 2011. 24: 371-373.
  138. Arends JE, Claassen MAA, van den Berg CHSB, Nanlohy NM, van Erpecum KJ, Baak BC, Hoepelman AIM, Boonstra A, van Baarle D. T-cell responses at baseline and during therapy with peginterferon-a and ribavirin are not associated with outcome in chronic Hepatitis C infected patients. Antiviral Res. 2010. 87: 353-360.
  139. Claassen MAA, de Knegt RJ, TurgutD, TilanusHW, JanssenHLA, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol. 2010. 52: 315-321.
  140. Woltman AM, Boonstra A, Janssen HLA. Dendritic cells in chronic viral hepatitis: victims or guardian angels? Gut. 2010. 59: 115-125.
  141. Boonstra A, van der LaanLJW, Vanwolleghem T, Janssen HLA. Experimental models for hepatitis C viral infection. Hepatology. 2009. 50: 1646-1655.
  142. Woltman AM, ter Borg MJ, BindaRS, SprengersD, von BlombergBME, ScheperRJ, HayashiK, NishiN, BoonstraA, van der MolenR, JanssenHLA. a-Galactosylceramide in chronic hepatitis B infection: results from a randomized placebo controlled phase I/II trial. Antivir Ther. 2009. 14: 809-818.
  143. Liu B, Janssen HLA, Boonstra A. Modulation of dendritic cell function by persistent viruses. Review. J Leukoc Biol. 2009. 85: 205-214.
  144. Stoop JN, Claassen MAA, Woltman AM, Binda RS, Kuipers EJ, Janssen HLA, van der Molen RG, Boonstra A. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients, and their frequency depends on the viral load. Clin Immunol. 2008. 129: 419-427.
  145. Boonstra A, Woltman AM, Janssen HLA. Immunology of hepatitis B and hepatitis C virus infections. Review. Best Pract Res Clin Gastroenterol. 2008. 22: 1049-1061.
  146. Boonstra A, Rasjbaum R, Holman M, Marques R, Asselin-PaturelC, Pereira J, Bates EEM, Akira S, Vieira P, Liu Y-J, Trinchieri G, O’Garra A. Macrophages and myeloid DC, but not plasmacytoid DC, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol. 2006. 177: 7551-7558.
  147. Sponaas AM, Cadman ET, Voisine C, Harrison V, Boonstra A, O’Garra A, Langhorne J. Malaria infection changes the ability of splenic DC populations to stimulate antigen-specific T cells. J Exp Med. 2006. 203: 1427-1433.
  148. Asselin-PaturelC, Brizard G, Chemin K, Boonstra A, O’Garra A, Vicari A, Trinchieri G. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005. 201: 1157-1167.
  149. Vieira PL, Christensen JR, Minaee S, O’Neill EJ, Barrat FJ, Boonstra A, Barthlott T, Stockinger B, Wraith DC, O’Garra A. IL-10 secreting regulatory T cells do not express FoxP3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004. 172: 5986-5993.
  150. Boonstra A, Asselin-PaturelC, Gilliet M, Crain C, TrinchieriG, Liu Y-J, O’GarraA. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential Toll-like receptor ligation. J Exp Med. 2003. 197: 101-109.
  151. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu X, Trinchieri G, O’Garra A, Liu Y-J. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by Flt3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med. 2002. 195: 953-958 (cited 269 times).
  152. Barrat FJ, Boonstra A, Cua DJ, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O’Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002. 195: 603-616.
  153. Asselin-PaturelC, Boonstra A, DalodM, DurandI, YessaadN, Dezutter-DambuyantC, VicariA, O’GarraA, Biron C, Brière F, TrinchieriG. The major type I interferon producing cells in the mouse are immature antigen-presenting cells exhibiting plasmacytoid morphology. Nature Immunol. 2001. 2: 1144-1150.
  154. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HFJ, O’Garra A. 1,25-dihydroxy-vitamin D3 has a direct effect on naïve CD4+ T cells to enhance the development of Th2 cells. J Immunol. 2001. 167: 4974-4980.
  155. Boonstra A, van Oudenaren A, Baert M, van Steeg H, Leenen PJ, van Der Horst GT, Hoeijmakers JH, Savelkoul HF, Garssen J. Ultraviolet-B-induced immunomodulation in XPA, XPC, and CSB DNA repair-deficient mice. J Invest Dermatol. 2001. 117: 141-146.
  156. Boonstra A, van Oudenaren A, Barendregt B, An L, Leenen PJM, Savelkoul HFJ. Ultraviolet B irradiation modulates systemic immune responses by affecting cytokine production of antigen-presenting cells. Int Immunol. 2000. 12: 1531-1538.
  157. Van Loveren H, Boonstra A, van Dijk MEA, Fluitman AJM, Savelkoul HFJ, Garssen J. UV exposure alters respiratory allergic responses in mice. Photochem Photobiol. 2000. 72: 253-259.
  158. Grinwis GCM, Boonstra A, van den Brandhof EJ, Dormans JAMA, Engelsma M, Kuiper RV, van Loveren H, Wester PW, Vaal MA, Vos JG. Short-term toxicity of bis(tri-n-butyltin)oxide in flounder (Platichtys flesus): Pathology and immune function. Aquatic Toxicology. 1998, 42: 15-36.
  159. Boonstra A, Savelkoul HFJ. The role of cytokines in ultraviolet-B induced immunosuppression. Eur Cytokine Network. 1997. 8: 117-123.

Chapters/ reports

  1. Woltman AM, Boonstra A, Naito M, Leenen PJM. Kupffer cells in health and disease. 2014.
  2. Boonstra A, Trinchieri G, O’Garra A. The plasticity of DC populations in promoting Th cell responses. In: “Handbook of Dendritic cells. Biology, Diseases and Therapy”. Editors: Lutz M, Romani N, Steinkasserer A. WILEY-VCH publishers. 2006. p.385-403.
  3. Boonstra A, Savelkoul HFJ. Activity of T cell subsets in allergic asthma. In: “New and Exploratory Therapeutics Agents for Asthma”. Editors: M. Yeadon & Z. Diamant. Marcel Dekker Inc. New York. 2000, p. 343-360.
  4. Boonstra A, Baert MRM, van der Velden VHJ, Savelkoul HFJ. Flowcytometric analysis of intracellular cytokines. In “Flowcytometric immunodiagnostics”. Editors: J.J.M. van Dongen and H. Hooijkaas. Immunology, Erasmus University Rotterdam. 1998. p. 83-94. (in Dutch).
  5. Boonstra A, Grinwis GCM, van Loveren H, Vaal MA, Wester PW, Vethaak AD, Vos JG. The development of ex vivo/ in vitro immune function tests in flounder. RIVM report number 732501001. 1996.